Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Broker tips: Hikma Pharmaceuticals, BAE Systems, Go-Ahead Group
(Sharecast News) - Barclays downgraded Hikma Pharmaceuticals on Friday to 'equalweight' from 'overweight' and cut the price target to 1,750.0p from 2,250.0p as it said a lack of visibility in the generics division was a real concern. On Thursday, Hikma downgraded revenue guidance for the generics segment to between $650.0m and $675.0m, from between $710.0m and $750.0m.
"Yes, Generics is a small part of Hikma's business, but it's been dominating the narrative so far this year," Barclays said.
"With yet another downward revision to numbers and without a permanent CEO, we think it is difficult to put new money into the name."
Analysts at Deutsche Bank raised their target price on aerospace and defence giant BAE Systems from 860.0p to 970.0p on Friday, stating the group was "still in a sweet spot".
Deutsche Bank raised its 2022-2025 estimates for BAE by 4-9%, as it modelled a stronger US dollar and also included the group's three-year £1.5bn buyback programme.
"These elements, coupled with a pension surplus and an improved midterm cash flow estimate, help to push our price target up to 970.0p," said DB, which reiterated its 'buy' rating on the stock.
The German bank also believes upside potential still remains, as a strong order pipeline should help spur extra growth, with BAE's portfolio increasingly returning to "the sweet spot" of global defence spending.
Jefferies downgraded Go-Ahead on Friday to 'hold' from 'buy' as it lifted its price target to 1,550.0p from 1,320.0p to reflect the increased takeover offer from Kinetic and Globalvia.
On Thursday, Australian bus group Kinetic and Spanish infrastructure specialist Globalvia lifted their takeover offer for the transport operator by £22.0m. The consortium upped its offer to £15.50 a share - comprising £14.50 in cash and a special dividend of £1 - from £15.00.
Jefferies said it was bumping up the share price and downgrading the rating as the shares are now trading around the new offer value.
Jefferies' base case is that the recommended offer from Kinetic and Globalvia is accepted and the deal closes. Its upside scenario is that another competing offer is made for Go-Ahead at a 10% premium to the Kinetic and Globalvia offer.
In the bank's downside scenario, the recommended offer from Kinetic and Globalvia receives insufficient shareholder support and lapses.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
